Lentiviral transductions with SREBP2 shRNA or NSC lentivirus. as a repressor and SREBP2 as an activator of DDAH transcription and activity. This study describes a novel mechanism of reciprocal regulation by the SREBP family members of the DDAH-ADMA system, which represents a potential link between cellular cholesterol content and endothelial dysfunction observed in cardiovascular Mitotane disease. Keywords:asymmetric dimethylarginine, dimethylarginine dimethylaminohydrolase, endothelial nitric oxide synthase a decrease in the bioavailabilityof the vasodilator nitric oxide (NO) is a hallmark of cardiovascular diseases including hypertension, atherosclerosis, and metabolic syndrome (6,9,44). One mechanism thought to be partially responsible for the reduction in NO and resultant endothelial dysfunction in these diseases is an increase in the levels of the endogenous inhibitor of NO synthase (NOS), asymmetric dimethylarginine (ADMA) (8,21,30,33,58). Increased P4HB plasma levels of ADMA are observed in patients with various forms of cardiovascular disease and, because of their correlation with adverse cardiovascular outcomes, have been suggested to be diagnostic biomarkers (29,31,42,64). Free ADMA is generated via protein methylation and subsequent protein hydrolysis (23) and is metabolized to citrulline and dimethylamine by dimethylarginine dimethylaminohydrolase (DDAH) (27,28,54). Because the metabolism of ADMA by DDAH isoforms 1 and 2 is the primary route of clearance of ADMA from the circulation (1,37,38,51), changes in the levels of DDAH expression and/or activity represent a possible mechanism leading to the accumulation of ADMA and the progression of endothelial dysfunction in cardiovascular disease. Indeed, a genetic deficiency in DDAH leads to increased plasma ADMA, endothelial dysfunction, and elevated blood pressure in mice (26), whereas an overexpression of DDAH lowers plasma ADMA, improves endothelial function, and lowers blood pressure (10,11,17,19,47,49). While a growing body of literature supports a role for DDAH in regulating the levels of ADMA and, consequently, endothelial function, the mechanisms of transcriptional regulation of DDAH expression are not completely understood. An analysis of the regulatory sequences of the DDAH genes identifies the response elements for nuclear hormone receptors including retinoid X receptor-, peroxisome proliferator-activated receptor-, and farnesoid X receptor (FXR). A stimulation of endothelial cells with retinoic acid, pioglitazone, and the FXR agonist GW-4064 has been reported to increase DDAH promoter activity (2) and expression (18,60), with differential regulation of DDAH1 and DDAH2 promoters by both FXR and retinoid X receptor- agonists. We observed that the stimulation of human umbilical vein endothelial cells (HUVECs) with simvastatin also leads to an increased expression of DDAH isoforms. One of the established mechanisms of simvastatin action is the activation of sterol Mitotane response element binding proteins (SREBPs), and we found that the promoter regions of both DDAH1 and DDAH2 contain recognition sites for Mitotane SREBP binding, with DDAH1 containing a higher number of SREBP response elements (SREs) than DDAH2. Since SREBP transcription factors have been shown to be disregulated both in endothelial dysfunction and metabolic disorders, we became interested in investigating their involvement in the regulation of DDAH expression. The purpose of the present study was to test the hypothesis that SREBP1c and SREBP2, Mitotane the major isoforms of SREBP expressed in endothelial cells, mediate the effects of simvastatin on the expression of DDAH1 and DDAH2. == MATERIALS AND METHODS == == == == Cell culture. == HUVECs were purchased from Lonza (Walkersville, MD) and cultured in EGM-2 media (Lonza) on Collagen I BioCoat cellware (BD Biosciences, Rockville, MD). EGM-2 media contains 0.3 mmol/l ofl-arginine. Cells ofpassages 36were used for all experiments. For statin studies, HUVECs were seeded at 1.5 105cells per well of a gelatin-coated 24-well plate, allowed to recover.